Dongsung Pharmaceutical Company Limited operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Dongsung Pharmaceutical Company Limited with three other
companies in this sector in KOREA (SOUTH) :
Humedix Co Ltd
sales of 98.48 billion Korean Won [US$84.30 million]
of which 78%
was Finished goods),
PharmGen Science Inc
(96.61 billion Korean Won [US$82.70 million]
of which 100%
was Pharmaceutical Segment), and
Hanall Biopharma Co Ltd
(88.60 billion Korean Won [US$75.84 million]
of which 100%
was Medical production and sales).
During the second
quarter of 2021, sales at Dongsung Pharmaceutical Company Limited totalled
22.96 billion Korean Won .
This is a drop of 12.3%
from the 26.19 billion Korean Won in sales at the company during the second quarter in 2020.
During the first two
quarters of 2021, sales totalled 45.27 billion Korean Won , which is
than through the first two quarters of 2020.
Dongsung Pharmaceutical Company Limited reported sales of 87.80 billion Korean Won (US$75.16 million)
December of 2020.
a very small
increase of 1.5%
versus 2019, when the company's sales were 86.54 billion Korean Won .
Despite this increase, sales are still
below the level achieved in 2018, when Dongsung Pharmaceutical Company Limited
reported sales of 91.91 billion Korean Won .
Sales of Cosmetics/toilet Preparation Segment saw an increase
that was more than double the company's growth rate: sales were up
19.1% in 2020, from
6.95 billion Korean Won to 8.28 billion Korean Won .
Not all segments of Dongsung Pharmaceutical Company Limited experienced an increase in sales in 2020:
sales of Pharmaceutical Segment fell 0.1% to 79.52 billion Korean Won .